The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal ...

The FDA announced a shift away from animal testing for drug approval, citing advanced alternatives like AI and organoids ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

The National Institute for Standards and Technology’s new harm reduction initiative is helping prevent needless deaths.

The president has reportedly urged Congress to pass $175 billion for border security. But residents say basic needs aren’t ...

Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) on Friday, April 11, announced that it has received final approval from the United ...

In the face of a drug crisis that’s killed more than 1,000 Albertans annually for years, the provincial government is poised ...

While 2025 began on a positive note for the pharmaceutical industry, things have taken a sharp turn amid escalating fears of ...